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Abstract: Antidepressants such as amitryptiline and fluoxetine are on the list of modern essential 
medicines of the World Health Organization. However, there are growing concerns regarding the 
ecological impact of these pharmaceuticals, leading to a great need to improve current wastewater 
treatment procedures. In this contribution, we will report on the use of molecularly imprinted 
polymers (MIPs) for the extraction of antidepressants in water samples. MIPs were developed for 
fluoxetine and duloxetine, antidepressants belonging to the class of selective serotonin reuptake 
inhibitors (SSRIs). The binding capacity of these microparticles was evaluated using ultraviolet–
visible (UV–Vis) spectroscopy. A new high-performance liquid chromatography (HPLC) procedure 
coupled to UV detection was developed, which enabled the study of mixtures of fluoxetine and 
duloxetine with other nitrogen-containing compounds. These results indicate that it is possible to 
selectively extract SSRIs from complex samples. Therefore, these versatile polymers are a promising 
analytical tool for the clean-up of water samples, which will benefit aquatic life and reduce the 
ecological impact of pharmaceuticals. 
Keywords: molecularly imprinted polymers; fluoxetine; selective serotonin reuptake inhibitors 
(SSRIs); optical batch rebinding; high-performance liquid chromatography 
 
1. Introduction 
Prescriptions of antidepressants are at an all-time high; in the last decade, the number of 
antidepressants that have been dispensed by pharmacies in the United Kingdom have increased by 
more than 100% [1]. Prozac is a common antidepressant that falls under the category of selective 
serotonin reuptake inhibitors (SSRIs). Fluoxetine (Figure 1), the active component of Prozac, inhibits 
the reuptake of serotonin in presynaptic neurons leading to an increased availability of serotonin [2]. 
Selective serotonin reuptake inhibitors are known to ease the symptoms of moderate to severe 
depression [3] and are used to complement treatment for a variety of disorders, such as obsessive-
compulsive disorder [4], bulimia nervosa [5], and panic disorders [6]. The World Health Organization 
has listed Prozac as one of the essential medicines in modern healthcare, demonstrating the 
importance of this drug [7].  
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With their increased use and availability, the environmental impact of these antidepressants 
becomes a greater concern. Pharmaceuticals are widely found in aquatic systems, which is due to a 
combination of low removal efficiency in sewage treatment plants (STPs) or a lack of available STPs 
[8]. The presence of SSRIs can have a significant impact on the serotonin levels of fish and other 
aquatic life, which plays a pivotal role in activity, aggression, and reproductive behavior [9,10]. 
Average surface water concentrations of fluoxetine can range from ≈0.01 to 1.4 µg/L depending on 
location [9]. Chu and Metcalfe [11] have demonstrated the bioaccumulation of SSRIs in fish, detecting 
the presence of fluoxetine and its active metabolite, norfluoxetine, in fish tissue. This has been 
confirmed by Brooks et al. [12], showing that the level of fluoxetine in organs in fish is similar to 
levels in the environment.  
 
 
 
Figure 1. Chemical structure of (a) ()-fluoxetine, (b) (S)-duloxetine, (c) clomipramine, and (d) 
caffeine. 
 
Liquid chromatography–mass spectrometry (LC–MS) [13,14], gas chromatography–mass 
spectrometry (GC–MS) [15], and nuclear magnetic resonance (NMR) spectrometry [16] are commonly 
used techniques for fluoxetine measurements, but these are costly, time-consuming, and frequently 
involve cumbersome procedures for sample preparation. High-performance liquid chromatography 
(HPLC) coupled to either ultraviolet–visible (UV–Vis) or fluorescent detection has the advantages of 
high selectivity and high sample throughput [17]. Here, we explore the use of molecularly imprinted 
polymers (MIPs) as sorbents due to their low-cost, high recovery, short removal time, and ability to 
perform extraction in aqueous samples. Molecularly imprinted polymers are porous polymers 
containing binding sites with high affinity for their target molecule [18,19]. These polymers can be 
easily tailored for multiple targets, which allows for the simultaneous extraction of fluoxetine as well 
as a range of other compounds within the same family of antidepressants.  
The reports on MIPs for fluoxetine detection in literature are sparse. Nezhadali et al. [20] 
reported the use of pyrrole as a functional monomer along with spectrophotometric determination 
to selectively detect fluoxetine. Barati et al. [21] synthesized MIPs as solid phase extraction (SPE) 
sorbents through coprecipitation, employing magnetic chitosan and graphene oxide as monomers. A 
range of biological and environmental samples was studied; however, the main drawback with this 
procedure is the time-consuming and complicated synthesis of the hybrid MIP structures, which is 
not scalable. Molecularly imprinted polymers for the detection of fluoxetine can also be combined 
with electrochemical sensing, as demonstrated by Alizadeh et al [22].  
For environmental purposes, it is preferable to detect a range of SSRIs instead of focusing solely 
on fluoxetine. We demonstrate that when imprinting fluoxetine as the template, we can develop 
materials that are suitable sorbents for fluoxetine but also other SSRIs, such as duloxetine (Figure 1). 
We monitor the extraction of a range of SSRIs with HPLC coupled to a UV–Vis detector. A range of 
monomers was evaluated, showing the design of the polymers was crucial to tuning the specificity 
and selectivity of the synthetic recognition elements. Similar levels of binding were achieved for all 
compounds within the fluoxetine family, indicating that these MIPs are powerful sorbents to be used 
during the pre-treatment of drug samples for analysis with HPLC. In the future, these materials are 
likely to have high potential for the treatment and clean-up of water samples and may be used in 
wastewater facilities. 
2. Materials and Methods 
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2.1. Reagents  
All solutions were prepared with deionized water or phosphate-buffered saline (PBS) solutions. 
Phosphate-buffered saline solutions were prepared using Dulbecco tablets obtained from Oxoid 
Limited (Basingstoke, UK). ()-Fluoxetine hydrochloride salt (99%), and (S)-duloxetine 
hydrochloride salt (99%) were both purchased from TCI Chemicals Ltd. (Oxford, UK). Clomipramine 
hydrochloride salt (98%), initiator azobisisobutyronitrile (AIBN) and caffeine were purchased from 
Sigma-Aldrich (Gillingham, UK). Methacrylic acid (MAA), ethylene glycol dimethacrylate 
(EGDMA), 2-(hydroxyethyl)methacrylate (HEMA), acrylamide (AA), itaconic acid (IA), acrylonitrile, 
2-vinylpyridine (2-VP), toluene, methanol, and dimethylsulfoxide (DMSO) were purchased from 
Acros (Loughborough, UK). Prior to polymerization, the stabilizers in all monomers and crosslinker 
monomers were removed by passing the solutions over a column packed with alumina (Sigma-
Aldrich). Solutions of HCl and NaOH (0.1 mM) in water were used to adjust the pH values of these 
solutions.  
2.2. Molecularly Imprinted Polymer Synthesis and Optimisation 
()-Fluoxetine hydrochloride (0.16 mmol) was dissolved in DMSO (7 mL) together with a 
functional monomer (0.32 mmol). The functional monomers that were used for the synthesis of 
fluoxetine MIPs (MIP-1-7) are described in Table 1. Subsequently, the crosslinker monomer (EGDMA, 
0.96 mmol) was added followed by the addition of the initiator (AIBN, 10 mg, 0.06 mmol). The 
solution was bubbled with N2 for five minutes, then heated to 65 °C to initiate the polymerization. 
The reaction was kept at constant temperature for 16 h, ensuring the polymerization reached 
completion. Next, the resulting polymer was ground into a fine powder using a planetary ball mill 
(model PM100, Retsch Ltd., Hope, UK), using a 50 mL stainless steel grinding jar and five stainless 
steel grinding balls of 1 cm diameter each. Three Soxhlet extractions were performed sequentially on 
the grounded polymer, with different solvent mixtures: (i) methanol/deionized water (50:50); (ii) 
acetonitrile/glacial acetic acid (50:50); and (iii) methanol/deionized water (50:50). The extraction was 
performed until no traces of the template were observed in the filtrate using UV–Vis spectroscopy. 
Thermogravimetric analysis (TGA) with a TG4000 from Perkin Elmer (London, UK) was performed 
to assess the stability of the polymer after extraction of the template. The particles were dried under 
vacuum for 16 h, reground, and sieved to obtain only particles with sizes smaller than <25 µm. 
Nonimprinted polymers (NIP-1–7) were prepared in the same manner but without the addition of 
the template during the polymerization. MIP-8 was also prepared using the same protocol and IA as 
monomer, but using a 1:1 mixture of fluoxetine and duloxetine as a template instead of just fluoxetine. 
To compare the specificity of the polymers towards fluoxetine, imprint factors (IFs) were determined 
by fitting the data with an allometric fit for concentrations of 0.05 and 0.25 mM.  
Table 1. Monomers used for the synthesis of fluoxetine MIPs-1–7. 
Molecularly Imprinted 
Polymer 
Monomer 
MIP-1 MAA 
MIP-2 IA 
MIP-3 HEMA 
MIP-4 Acrylamide 
MIP-5 Acrylonitrile 
MIP-6 MAA + IA (1:1) 
MIP-7 MAA + HEMA (1:1) 
HEMA: 2-(Hydroxyethyl)methacrylate; IA: Itaconic acid; MMA: Methacrylic acid. 
2.3. Batch Rebinding Experiments Evaluated by UV–Vis Analysis 
Optical batch rebinding experiments were evaluated by measuring absorbance values (λmax = 
264 nm) of the solutions with an Agilent 8453 spectrophotometer (Stockport, UK). For each 
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experiment, MIP or NIP powder (10 mg) was added to several solutions of antidepressants in PBS (5 
mL) with different known concentrations. The resulting suspensions were placed on a STUART SSM1 
orbital shaker (Cole-Palmer, Stone, UK) at 125 rpm for 90 min and passed through 0.45 µm filters 
prior to UV–Vis analysis.  
Various fluoxetine concentrations, ranging from 0 to 1.5 mM in PBS, were used to construct dose-
response curves for MIP-1–7. These curves were then employed to determine the free concentration 
of the template in the filtered solutions (Cf) by dividing the absorbance over the gradient of the 
calibration curve. Subsequently, the amount bound to template (Cb) was calculated by subtracting the 
initial concentration added to the solution (Ci) by the free template concentration of the filtered 
solution (Cf). The moles of template bound per gram of polymer (Sb) was obtained by dividing Cb × 
V, where V is the volume in liters, over the amount of polymer added in the rebinding experiment 
(10 mg). The IF was determined by dividing the Sb for a given MIP by the Sb for the corresponding 
NIP. 
As a measure of specificity and in order to compare the different MIP compositions, the IF was 
determined at a free concentration of the template (Cf) of 0.05 and 0.2 mM. This was done by fitting 
the MIP data with an allometric fit (y = axb) which is in line with the heterogeneity of the binding sites. 
The data generated with the NIP, in general, followed a linear fit line, which is to be expected for 
nonspecific binding. The amount of analyte bound at Cf was determined according to the fit for both 
MIPs and NIPs, with an IF calculated at a given concentration.  
These experiments were performed in a wider concentration regime to determine when 
saturation of the binding sites would occur, providing a more accurate fit for the calculation of the 
IFs. 
2.4. Batch Rebinding Experiments Evaluated by HPLC 
Rebinding experiments were conducted according to the same protocol described in section 2.3., 
which includes mixing the corresponding MIP or NIP powder (10 mg) with PBS solutions (5 mL) of 
known concentrations of SSRIs or caffeine. After placing those suspensions on an orbital shaker for 
90 min, the samples were passed through a Fisherbrand PTFE 0.45 µm filter membrane (Fisher 
Scientific, Loughborough, UK). The resulting solutions were analyzed with an Agilent 1100 Series 
HPLC equipped with a G1315B diode array detector and a Quat Pump G1311A (Agilent 
Technologies, Waldbronn, Germany) equipped with a 100-place auto-injector and diode-array UV 
absorbance detector (DAD) (220 nm). Caffeine is an important anthropogenic marker in surface 
water, and its levels can be directly related to water quality [23]. The chemical structure is 
significantly different from the studied SSRIs and therefore, it was used in experiments to study the 
selectivity, since it is important that the developed analytical tool can discriminate between various 
classes of micropollutants.  
Data analysis was carried out using ChemStation for LC software (version 10.02, Agilent 
Technologies, Wokingham, UK). Measurements were performed in triplicate in order to determine 
the standard deviation of the signal. Two sets of experimental parameters were used, one for the 
analysis of the individual antidepressants and one for the mixture of them. Both the initial (Ci) and 
the free (Cf) concentration were analyzed for binding.       
For individual analysis, a Hypersil ODS-2 C18 HPLC column (5 µm particle size, 150 × 4.6 mm, 
Thermo Fisher Scientific, Waltham, MA, USA) was used with a flow rate of 1.1 mL/min. The mobile 
phase was a 75:25 (v/v) mixture of acetonitrile and orthophosphoric acid solution (0.1% H3PO4 (aq), 
pH 2.1), with the injection volume set at 10 µL. For the mixed samples, a longer column (Gemini C18 
HPLC column, 5 µm particle size, 250 × 4.6 mm, Phenomenex, Inc., Macclesfield, UK) was used along 
with sodium acetate buffer (pH 4.5) in the mobile phase to facilitate discrimination between the 
various drugs. The mobile phase was composed of the buffer along with acetonitrile and methanol 
(6.5:3.2:0.3), which was run at a flow rate of 1.1 mL/min using an injection volume of 20 µL. 
3. Results and Discussion 
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3.1. Synthesis and Characterisation of Fluoxetine MIPs and NIPs 
MIPs-1–7 and NIPs-1–7 polymers were synthesized in quantitative yields and analyzed via TGA. 
Thermogravimetric analysis analysis showed that the polymers were stable up until temperatures of 
200 °C (Supplementary Figure S1). Rebinding experiments with MIP-1 and NIP-1 were performed to 
determine the influence of the time on binding of fluoxetine, with measurements taken at 15, 30, 60, 
90, 120, 240, and 1020 min. The optimal binding time was seen as the shortest time at which high 
specific binding of fluoxetine was achieved. It was found that there was no significant increase in 
specific binding after 90 min, and therefore the binding time was fixed to this time in further 
experiments. The pH was kept neutral, as no significant difference between binding at pH 5 and 7 
was observed, which meant adjustments of the PBS buffer were unnecessary (see Supplementary 
Figure S2). The size and morphology of the resulting particles was characterized by scanning electron 
microscopy (SEM) (see Supplementary Figure S3), with the size distribution ranging from 
approximately 1 to 25 µm (with some agglomeration during the preparation of the SEM sample). 
3.2. Monomer Optimization Study  
Batch rebinding experiments were performed with PBS solutions (pH 7) containing fluoxetine 
concentrations ranging from 0 to 1 mM using UV–Vis spectrophotometry as the read-out technique. 
Binding isotherms were constructed by using both results obtained by UV–Vis and HPLC analysis. 
The binding of fluoxetine to the MIP and NIP layers is provided in Table 2. Imprint factors were 
calculated at two different concentrations for accuracy. An allometric fit was used to describe the MIP 
data, with all R2 values above 0.9. The data obtained for NIPs was best described with a linear 
correlation due to the nonspecific nature of the fluoxetine binding to the NIP layer.  
Table 2. Fluoxetine binding of MIPs and NIPs with various compositions as determined by UV–Vis 
spectroscopy. 
Polymer 
Binding at Cf = 
0.05 mM 
Imprint factor (Cf = 
0.05 mM) 
Binding at Cf = 0.2 
mM (Sb/Cf) 
Imprint factor (Cf = 
0.2 mM) 
MIP-1 1240 
2.1 
1250 
2.2 
NIP-1 600 575 
MIP-2 900 
5.6 
850 
6.3 
NIP-2 160 135 
MIP-3 1320 
2.8 
1300 
2.8 
NIP-3 480 465 
MIP-4 360 
2.6 
370 
2.6 
NIP-4 140 145 
MIP-5 300 
1.1 
290 
1.1 
NIP-5 260 255 
MIP-6 3600 
7.2 
3555 
7.2 
NIP-6 500 495 
MIP-7 520 
2.0 
525 
1.5 
NIP-7 320 340 
 
MIP-1–3, synthesized with methacrylic-based monomers (MAA, IA, and HEMA, respectively; 
Table 1) exhibited a high amount of specific binding to fluoxetine (Table 2). The highest IF was 
achieved for MIP-2, probably due to higher charge density of the IA monomer, provided with two 
carboxylic acid groups [24]. MIP-4 and MIP-5, prepared using acrylamide and acrylonitrile, 
respectively, as the functional monomers, did not show any specificity towards the template, 
probably due to weak interactions between the amide and cyano group in the monomer and the 
amine on fluoxetine. MIP-6 and MIP-7 (Table 1) were prepared to evaluate the possible synergistic 
effect of having two functionalized monomers MAA/IA and MAA/HEMA, respectively. From the 
results (Table 2), we can see that MIP-6 has a very large IF but suffers from nonspecificity, as NIP-6 
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has a high degree of binding. MIP-7, on the other hand, does not benefit from the monomer mixture 
and shows low specificity. Based on the results, MIP-2, whose corresponding NIP-2 showed the 
lowest binding (Figure 2), was further evaluated for its recognition capability towards fluoxetine, 
duloxetine, clomipramine, and caffeine (Figure 1), using HPLC analysis.  
 
Figure 2. Binding isotherms of MIP-2 for the binding of fluoxetine (open squares), duloxetine (solid 
squares), clomipramine (open circles) and caffeine (solid circles).  
Caffeine is substantially different in structure from the other compounds, and thus shows 
minimal binding to MIP-2. This is clear from Figure 2, where binding does not exceed 20 µmol/g for 
caffeine whereas the other compounds all bind more than 600 µmol/g. Binding of fluoxetine at Ci = 
0.75 was equal to ≈800 µmol/g, similar to the results obtained to clomipramine. The fact that 
clomipramine (bearing a tertiary amine) behaves the same as fluoxetine (provided with a secondary 
amine) suggests that binding may not only be caused by H bonding but also by other noncovalent 
interactions. The binding of duloxetine at lower initial concentrations is similar to both these two 
compounds, but the overall binding capacity of ≈600 µmol/g is slightly lower. The reason for this 
could be that these compounds share a similar pharmacophore, and the main interaction of the 
functional monomer is with the nitrogen.  
3.3. HPLC Analysis of SSRI Mixtures 
The viability of the method to separate mixtures from compounds of the same drug family was 
first evaluated by measuring a mixture with 1:1 ratio with each of the other compounds (Ci = 0.75 
mM). MIP-2 was used in these experiments, with fluoxetine as the template. Since HPLC is able to 
separate out this mixture, it can be determined whether binding to the polymers is a competitive 
process and what level of selectivity can be achieved. The binding time was kept at 1 h but the amount 
of the polymer was reduced from 10 to 5 mg due to the higher injection volume used in these 
measurements. This prevented saturation of the signal, and measured peak areas would fall within 
the calibration range. The retention time for all compounds is provided in Supplementary Table S1 
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and chromatograms are included in Supplementary Figures S4–S7. All compounds were present in 
an equimolar ratio. 
Measurements were performed in a 0–0.75 mM concentration range in PBS. In each experiment, 
fluoxetine was present in a 1:1 ratio with another compound of the same family (duloxetine, and 
clomipramine) as well as structurally different drugs (caffeine) which allows competition for binding 
to occur. These mixtures are more representative for real samples, which will be composed of a 
variety of compounds present in different ratios. The differences in binding at a concentration of 0.25 
mM between MIP-2 and NIP-2 for fluoxetine in the presence of other compounds are listed in Table 
3. In addition, the binding of two other SSRIs and caffeine when mixed with fluoxetine is compared 
between MIP-2 and NIP-2 at a concentration of 0.25 mM.  
Table 3. Imprint factors for MIP-2 and NIP-2 of fluoxetine in solutions containing both fluoxetine and 
other drug compounds at 0.25 mM.  
Compounds Mixture IF for Fluoxetine 
 MIP/NIP Comparison 
Compounds 
Fluoxetine:Duloxetine 1.45 1.26 
Fluoxetine:Clomipramine 1.58 1.37 
Fluoxetine:Caffeine 2.19 0.71 
 
As expected, there is no difference in binding for MIP and NIP towards caffeine, as its structure 
is significantly different from fluoxetine. Fluoxetine had the highest specific binding compared to the 
other compounds, which shows that there is still an increased preference for the imprinted molecule 
even when there are substantial similarities in structure between the competing species. However, 
the imprint factors are significant lower compared to Table 2. This suggests that competition is indeed 
occurring and compounds within the same drug family can be bound to some degree with a single 
template.  
3.4. Dual Imprinted Polymer with Fluoxetine and Duloxetine 
 The presence of multiple templates on the MIPs’ performance was explored using fluoxetine and 
duloxetine. MIP-8 was prepared using IA as monomer and an equimolar mixture of fluoxetine and 
duloxetine as template. Batch rebinding experiments were performed on the resulting polymer MIP-
8 (along with the nonimprinted corresponding analogue NIP-8) as previously outlined, with a 
concentration range from 0 to 2.5 mM for fluoxetine and duloxetine each (only fluoxetine was studied 
for NIP-8) in PBS. The results analyzed by HPLC are shown in Figure 3. 
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Figure 3. Dose–response curves of MIP-8 for fluoxetine (solid squares) and duloxetine (open squares), 
as well as for a nonimprinted polymer with fluoxetine (solid circles). 
Both targets were successfully bound by the polymer, with increased levels seen at each 
concentration relative to the NIP. This demonstrates that both molecules can be imprinted 
simultaneously without inhibiting the polymer’s ability to rebind. Interestingly, more of the 
fluoxetine compared to the duloxetine was bound at lower concentrations, indicating the developed 
polymers had a preference for one target molecule. At higher concentrations, where binding sites are 
increasingly occupied, the binding of both target molecules converged. This indicates there is no 
significant difference between binding capacities of these polymers for the two target molecules, but 
there is a difference in the affinity of binding sites for fluoxetine and duloxetine. A larger library of 
these materials should be prepared in order to gain further insight in the properties of these dual-
imprinted polymers.  
4. Conclusions 
Imprinted polymers were successfully synthesized and optimized for fluoxetine, with various 
functional monomers investigated. The resulting material showed strong binding of the target 
molecule as well as compounds within the same drug family. Analysis using HPLC was able to show 
preferential binding of the target to the MIP for solutions containing multiple SSRIs although 
evidence of competition was present. These results indicate that high selectivity for SSRIs can be 
obtained using low-cost, easily synthesized imprinted polymers. Experimental parameters, such as 
concentration ratios and absorption time, can be adjusted in the future to tune the MIP’s selectivity 
further. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: 
Thermogravimetric analysis curves for MIP-1, -2, -3, -6, and -7, Figure S2: Influence of binding time and pH on 
binding of the template to MIPs, Figure S3: Size and morphology of particles, Figure S4: Chromatogram for 
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fluoxetine, Figure S5: Chromatogram for duloxetine, Figure S6: Chromatogram for clomipramine, Figure S7: 
Chromatogram for caffeine, Figure S8: FTIR spectrum of MIP-2 imprinted with fluoxetine, Table S1: HPLC 
retention times of the compounds fluoxetine, duloxetine, clomipramine, and caffeine. 
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